TY - JOUR
T1 - European Surveillance System on Contact Allergies (ESSCA)
T2 - polysensitization, 2009-2014
AU - ESSCA Network
AU - Dittmar, Daan
AU - Uter, Wolfgang
AU - Bauer, Andrea
AU - Fortina, Anna B.
AU - Bircher, Andreas J.
AU - Czarnecka-Operacz, Magdalena
AU - Dugonik, Aleksandra
AU - Elsner, Peter
AU - Gallo, Rosella
AU - Ghaffar, Sharizan A.
AU - Gimenez-Arnau, Ana
AU - Johnston, Graham A.
AU - Krecisz, Beata
AU - Filon, Francesca L.
AU - Rustemeyer, Thomas
AU - Sadowska-Przytocka, Anna
AU - Sanchez-Perez, Javier
AU - Schnuch, Axel
AU - Simon, Dagmar
AU - Spiewak, Radoslaw
AU - Spring, Philipp
AU - Corradin, Maria T.
AU - Valiukeviciene, Skaidra
AU - Vok, Marko
AU - Weisshaar, Elke
AU - Wilkinson, Mark
AU - Schuttelaar, Marie L.
PY - 2018/6
Y1 - 2018/6
N2 - Background. Polysensitization, defined as being allergic to three or more haptens from the European baseline series, is considered to reflect increased susceptibility to developing a contact allergy, and is likely to be associated with an impaired quality of life.Objectives. To evaluate the prevalences of polysensitization across Europe and to analyse factors associated with polysensitization.Methods. Patch test data collected by the European Surveillance System on Contact Allergies (ESSCA; www.essca-dc.org) in consecutively patch tested patients from January 2009 to December 2014, comprising 11 countries and 57 departments, were retrospectively analysed.Results. A total of 86 416 patients were available for analysis, showing a standardized prevalence of polysensitization of 7.02%, ranging from 12.7% (Austria) to 4.6% (Italy). Allergen pairs with the strongest association are reported for the total population, for South Europe, and for North/Central Europe. Overall, polysensitized patients showed a higher percentage of extreme (+++) positive patch test reactions than oligosensitized patients. Female sex, occupational dermatitis and age > 40 years were risk factors for polysensitization.Conclusions. The varying prevalences of polysensitization across Europe most likely reflect differences in patient characteristics and referral patterns between departments. Knownrisk factors for polysensitization are confirmed in a European dermatitis population.
AB - Background. Polysensitization, defined as being allergic to three or more haptens from the European baseline series, is considered to reflect increased susceptibility to developing a contact allergy, and is likely to be associated with an impaired quality of life.Objectives. To evaluate the prevalences of polysensitization across Europe and to analyse factors associated with polysensitization.Methods. Patch test data collected by the European Surveillance System on Contact Allergies (ESSCA; www.essca-dc.org) in consecutively patch tested patients from January 2009 to December 2014, comprising 11 countries and 57 departments, were retrospectively analysed.Results. A total of 86 416 patients were available for analysis, showing a standardized prevalence of polysensitization of 7.02%, ranging from 12.7% (Austria) to 4.6% (Italy). Allergen pairs with the strongest association are reported for the total population, for South Europe, and for North/Central Europe. Overall, polysensitized patients showed a higher percentage of extreme (+++) positive patch test reactions than oligosensitized patients. Female sex, occupational dermatitis and age > 40 years were risk factors for polysensitization.Conclusions. The varying prevalences of polysensitization across Europe most likely reflect differences in patient characteristics and referral patterns between departments. Knownrisk factors for polysensitization are confirmed in a European dermatitis population.
KW - clinical epidemiology
KW - contact allergy
KW - patch test
KW - polysensitization
KW - BASE-LINE SERIES
KW - PATCH-TEST REACTIONS
KW - DERMATITIS-RESEARCH-GROUP
KW - ANGRY BACK SYNDROME
KW - QUALITY-OF-LIFE
KW - INFORMATION-NETWORK
KW - P-PHENYLENEDIAMINE
KW - DERMATOLOGY IVDK
KW - GENETIC-FACTORS
KW - SUSCEPTIBILITY
U2 - 10.1111/cod.12966
DO - 10.1111/cod.12966
M3 - Article
VL - 78
SP - 373
EP - 385
JO - CONTACT DERMATITIS
JF - CONTACT DERMATITIS
SN - 0105-1873
IS - 6
ER -